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Abstract Artificial proteins can be engineered to exhibit
interesting solid state, liquid crystal or interfacial properties
and may ultimately serve as important alternatives to conven-
tional polymeric materials. The utility of protein-based materials
is limited, however, by the availability of just the 20 amino acids
that are normally recognized and utilized by biological systems;
many desirable functional groups cannot be incorporated directly
into proteins by biosynthetic means. In this study, we incorporate
para-bromophenylalanine (p-Br-phe) into a model target protein,
mouse dihydrofolate reductase (DHFR), by using a bacterial
phenylalanyl-tRNA synthetase (PheRS) variant with relaxed
substrate specificity. Coexpression of the mutant PheRS and
DHFR in a phenylalanine auxotrophic Escherichia coli host
strain grown in p-Br-phe-supplemented minimal medium resulted
in 88% replacement of phenylalanine residues by p-Br-phe;
variation in the relative amounts of phe and p-Br-phe in the
medium allows control of the degree of substitution by the
analog. Protein expression yields of 20^25 mg/l were obtained
from cultures supplemented with p-Br-phe; this corresponds to
about two-thirds of the expression levels characteristic of
cultures supplemented with phe. The aryl bromide function is
stable under the conditions used to purify DHFR and creates new
opportunities for post-translational derivatization of brominated
proteins via metal-catalyzed coupling reactions. In addition,
bromination may be useful in X-ray studies of proteins via the
multiwavelength anomalous diffraction (MAD) technique.
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1. Introduction
Protein engineering provides a powerful tool for modi¢ca-
tion of the structural and functional properties of proteins as
well as for designing new macromolecular substances with
precise control of composition and architecture. Several poly-
meric materials with interesting properties have been synthe-
sized by protein engineering methods [1^4]. For many appli-
cations of these macromolecules, it will be desirable to
develop methods for incorporation of amino acids containing
novel chemical functionality not possessed by the 20 proteino-
genic amino acids. New functionality can be exploited to
probe protein structure and function, to alter stability and
folding behavior, and to open new avenues for post-transla-
tional modi¢cation.
Biosynthetic incorporation of non-canonical amino acids
into proteins has been achieved in Escherichia coli largely by
exploiting the capacity of the wild-type protein synthesis ap-
paratus to utilize analogs of the natural amino acids [5^11].
However, use of a wider range of analogs will require that the
substrate speci¢city of the aminoacyl-tRNA synthetases
(aaRS) is relaxed or changed altogether. The in vitro method
of unnatural amino acid incorporation, introduced by Hecht
and coworkers [12], uses chemically acylated tRNAs and
thereby circumvents the checkpoint of the aaRS; this method
has found extensive application in amino acid replacement in
a site-speci¢c manner [13^15]. A further advance in site-spe-
ci¢c replacement was the demonstration of in vivo incorpo-
ration of an amino acid analog by using a yeast suppressor
tRNAamber/aaRS pair in an analog-resistant E. coli strain [16].
We have previously exploited the ability of E. coli to incor-
porate para-£uorophenylalanine (p-F-phe) into repetitive pol-
ypeptides with high e⁄ciency [10]. While £uorinated polypep-
tide materials are likely to exhibit novel surface properties,
they are inert to chemical modi¢cation under mild conditions.
We therefore turned our attention to para-bromophenylala-
nine (p-Br-phe), which we anticipate will be readily modi¢ed
owing to the higher reactivity of the aryl bromide functional
group [17^22]. Moreover, bromination may be useful in X-ray
structure determination of proteins by multiwavelength anom-
alous di¡raction (MAD). Brominated nucleic acids have been
used successfully for determination of the structures of DNA^
drug complexes, DNA^protein complexes, DNAs and RNAs
[23^27]. We suggest that p-Br-phe may eventually complement
selenomethionine [28,29] in structure determination of pro-
teins by the MAD technique.
While the wild-type E. coli protein synthesis machinery can
utilize phenylalanine (phe) and p-F-phe, the analog p-Br-phe
is not recognized by the wild-type phenylalanyl-tRNA synthe-
tase (PheRS). In 1991, however, Kast and Hennecke reported
an engineered mutant form of this enzyme (Gly294PheRS)
which charges tRNAPhe with p-Cl-Phe in vivo and appears
to enable incorporation of even p-Br-phe into cellular protein
[30^32]. In the present work, we employed this mutant to
e¡ect e⁄cient in vivo incorporation of p-Br-phe into mouse
dihydrofolate reductase (DHFR) in bacterial cells.
2. Materials and methods
2.1. Plasmids and E. coli strains
The plasmid pKSS bears the gene for the Gly-294 variant K-subunit
of the PheRS (termed pheS*) [33]. pheS* was subcloned from pKSS
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by PCR mutagenesis such that two SphI restriction sites, one at either
end outside of the pheS* gene, were generated by single-base inser-
tions (SphI sites were designed for another purpose). The 1722 bp
PCR-ampli¢ed fragment was cloned into a pUC19 cloning vector at
the SmaI site. The pheS* gene was cut out as an SphI fragment, blunt-
ended, and inserted into the PvuII site of the expression plasmid
pQE15 (Qiagen). The resulting plasmid, designated pQE-FS, carries
the gene for the target protein DHFR under bacteriophage T5 pro-
moter control and that for pheS* under lac promoter control. The
repressor plasmid pLysS (Novagen) was modi¢ed so that it contained
the lacIq gene for lac repressor as a SalI fragment from the plasmid
pREP4 (Qiagen); the resulting plasmid was designated pLysS-IQ.
A phenylalanine auxotrophic derivative of E. coli strain
BL21(DE3), called AF, previously constructed in our laboratory,
was used as host [10]. The AF strain with the repressor plasmid
pLysS-IQ was designated AF-IQ. AF-IQ cells were transformed
with pQE-FS or with control plasmid pQE15.
2.2. Gene expression and incorporation of p-Br-phe into DHFR
The in vivo translational activity of p-Br-phe was ¢rst investigated
on a small scale. Bacterial cultures were grown in M9 minimal me-
dium [34] supplemented with glucose, thiamine, MgSO4, CaCl2, 19
amino acids (at 20 mg/l), antibiotics (ampicillin and chloramphenicol)
and phenylalanine (at 20 mg/l). AF-IQ[pQE15] and AF-IQ[pQE-FS]
cultures were grown in supplemented M9 medium containing phe. At
an optical density at 600 nm (OD600) of 0.8^1.0, cells were sedimented
by centrifugation, washed twice with 0.9% NaCl and resuspended in
supplemented M9 medium containing either: (i) 500 mg/l p-Br-phe,
(ii) 20 mg/l phe (positive control) or (iii) no phe or analog (negative
control). Gene expression was induced 10 min after the medium shift
by addition of isopropyl-L-D-thiogalactoside (IPTG) to a ¢nal concen-
tration of 1 mM. Cells were harvested 4 h post-induction and protein
expression was monitored by analysis of whole cell lysates on sodium
dodecyl sulfate (SDS)^polyacrylamide gel electrophoresis (PAGE).
Larger scale production of DHFR was carried out in 1 l cultures of
AF-IQ[pQE-FS] grown in the medium described above. Cells were
sedimented and the cell pellet was resuspended in supplemented M9
medium containing p-Br-phe at 500 mg/l; expression of DHFR was
induced 10 min after the medium shift with 1 mM IPTG. In experi-
ments to control the degree of bromination of DHFR, the induction
medium was supplemented with varying amounts of phe and p-Br-phe
(see Table 1).
2.3. Isolation and analysis of brominated target protein
DHFR as expressed from pQE15-derived plasmids contains an N-
terminal hexahistidine sequence, which was utilized for protein puri-
¢cation by nickel-a⁄nity chromatography with step-wise pH gradient
elution under denaturing conditions (Qiagen). Eluted protein was dia-
lyzed against distilled water and lyophilized, and the puri¢ed protein
was subjected to amino acid compositional analysis.
2.4. Extraction of cellular free amino acids
In order to determine the cellular concentrations of free phe and p-
Br-phe, 250 ml cell cultures were grown in M9 medium supplemented
with all 20 amino acids at 20 mg/l. The cells were harvested at
OD600 = 1, washed twice with 0.9% NaCl and treated as follows: (i)
subjected to analysis as such, or (ii) incubated for 2 h in M9 medium
lacking phe and containing IPTG, p-Br-phe, both or neither as de-
scribed in Fig. 2. Free amino acids were extracted by a modi¢ed
version of the protocol of Raunio and Rosenqvist [35] ; harvested cells
were resuspended in 5 ml distilled water, and the suspension adjusted
to pH 10 with a few drops of 5 N NH4OH. The suspension was
incubated without shaking for 10 min at 100‡C in a water bath. After
cooling, the pH was adjusted to about 2 by addition of HCl. The
precipitate thus obtained was removed by centrifugation at 4000Ug
for 10 min at 4‡C. The supernatant was frozen and a 100 Wl aliquot
was lyophilized and subjected to amino acid compositional analysis.
Similar experiments were conducted using M9 medium supplemented
(at 20 mg/l) with just the three amino acids that are essential for
growth of the AF strain viz. proline, arginine and phenylalanine.
3. Results
3.1. Gly294PheRS allows p-Br-phe incorporation into proteins
An AF-IQ[pQE-FS] culture was grown in supplemented
M9 minimal medium to an OD600 of 0.8^1.0, and then shifted
to a medium containing either (i) p-Br-phe, (ii) phe (positive
control) or (iii) no phe or p-Br-phe (negative control). Expres-
sion of DHFR was induced for 4 h with 1 mM IPTG. A
control expression experiment was done with AF-IQ[pQE15],
which contains only the wild-type PheRS. No expression of
DHFR was observed in the negative control cultures or in the
AF-IQ[pQE15] culture containing p-Br-phe. On the other
hand, AF-IQ[pQE-FS] cultures supplemented with p-Br-phe
expressed DHFR (albeit at lower levels than the positive con-
trols), as noted from SDS^PAGE analysis of the respective
whole cell lysates (Fig. 1). The target proteins were puri¢ed by
nickel-a⁄nity chromatography. The yield of puri¢ed target
protein isolated from AF-IQ[pQE-FS] cells grown in p-Br-
phe-supplemented medium (DHFR-Br) was 20^25 mg/l,
which is approximately 70% of the yield of DHFR obtained
from the same cells grown in medium supplemented with phe.
Amino acid analysis of puri¢ed DHFR-Br indicated up to
88% substitution of phe residues (there are nine phe residues
in DHFR) by p-Br-phe. The decrease in phe content was
compensated by an increase in p-Br-phe content, indicating
that p-Br-phe is stable under the conditions of protein puri¢-
cation and amino acid analysis.
3.2. Control of degree of substitution
For many purposes of post-translational chemical modi¢-
cation of proteins, complete substitution by the analog may
not be necessary (or may even be detrimental). We explored
the possibility of gaining control over p-Br-phe incorporation
Table 1
Control of the level of p-Br-phe incorporation
Experiment p-Br-phe (mg/l) Phe (mg/l) Yield of DHFR (mg/l culture) p-Br-phe (%)
1 0 20 36 0
2 250 20, no media shift 55 10
3 500 20, no media shift 30 10
4 500 8, no media shift 28 60
5 250 0 20 46
6 500 0 24 88
7 750 0 24 87
8 1000 0 22 78
9 500 1 28 70
10 500 2 30 65
11 250 2 30 20
Cells were grown to an OD600 of 1, harvested, washed twice and then shifted to medium containing the indicated amounts of phe and p-Br-
phe. No media shift indicates that the cells were not washed and in that case, phe indicates the initial concentration supplied at the start of the
culture.
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by supplementing the medium with varying amounts of phe
and p-Br-phe during target protein expression. AF-IQ[pQE-
FS] cells were grown in M9 medium as before and shifted to
media containing the amounts of phe and p-Br-phe indicated
in Table 1. The results shown in Table 1 compare the levels of
p-Br-phe incorporation and the yields of protein obtained for
di¡erent concentrations of phe and p-Br-phe. The bromina-
tion level increases with increasing concentrations of p-Br-phe
up to 500 mg/l ; higher concentrations of p-Br-phe do not
change the degree of incorporation further under our condi-
tions (experiments 5^8). Addition of phe along with p-Br-phe
improves the yield of protein modestly while reducing the
degree of bromination as expected (experiments 9^11). Addi-
tion of p-Br-phe to growing cultures at the time of induction
without the removal of phe resulted in very low levels of
incorporation of the analog when the initial phe concentration
was high (i.e. 20 mg/l). When the culture medium initially
contained only 8 mg/l of phe, the level of substitution in-
creased to about 60% (experiments 2^4).
3.3. Determination of free amino acids in the cell
In an attempt to understand why we did not observe com-
plete replacement of phe by p-Br-phe, we determined the in-
tracellular concentrations of free phe and p-Br-phe in AF-
IQ[pQE-FS] cells under di¡erent growth conditions. We
were particularly interested in the possibility that starvation
for phe, induction of the T5 promoter and subsequent over-
expression of DHFR, addition of p-Br-phe or a combination
of these events might lead to a stress response and enhance
cellular protein turnover, thereby increasing the cellular pool
of phe. Cells were grown in the presence of phe, washed twice
with saline and then grown in the presence of IPTG, p-Br-phe,
or both, as described in Section 2. After 2 h of incubation, the
amounts of free cellular phe and p-Br-phe were determined.
The results in Fig. 2 indicate that the phe concentration does
not vary signi¢cantly under the conditions examined and re-
mains at 0.65 þ 0.15 WM, signi¢cantly lower than that supplied
to the medium (120 WM). The concentration of cellular p-Br-
phe was found to be 14^17 times higher than that of phe, but
remained in the micromolar range even when the amount
supplied to the culture medium was in the millimolar range.
Similar results were obtained when cells were grown in the
presence of just the three amino acids essential for growth
of the AF strain. Incomplete replacement of phe thus appears
to be a simple consequence of the fact that the medium shift
does not remove the last traces of the natural amino acid from
the culture.
4. Discussion
Incorporation of p-Br-phe into short peptides by solid state
peptide synthesis has been reported previously [36^38]. The
results reported here constitute the ¢rst demonstration of an
e⁄cient strategy for incorporation of p-Br-phe into protein in
vivo. This was achieved by coexpression of the gene for a
PheRS variant with relaxed substrate speci¢city, along with
the gene encoding the protein of interest, in an E. coli host
strain auxotrophic for phenylalanine. The E. coli strain we use
still expresses its wild-type PheRS K-subunit; however, since
the mutant PheRS K-subunit is produced from several plas-
mid-borne gene copies, most functional PheRS molecules
(which have the oligomeric structure [KL]2 [39,40]) are likely
to contain the mutant subunit and thus possess the ability to
utilize p-Br-phe. High levels of replacement (88%) of phenyl-
alanine by its brominated analog have been achieved. The
brominated analog is stable once incorporated into protein,
and the yield of brominated protein is high enough for sam-
ple-intensive methods such as post-translational modi¢cation,
nuclear magnetic resonance or crystallographic structure de-
termination.
Controlling the amount of p-Br-phe substitution may be
advantageous for many applications, e.g. post-translational
modi¢cation, as it may not be necessary to replace all of the
phenylalanine residues by the brominated analog. The level of
analog incorporation can be controlled by varying the relative
amounts of phe and p-Br-phe in the culture medium at the
time of induction of target gene expression. The success
shown here with the model protein (DHFR) is likely to be
applicable to other proteins as well.
The in vivo method for unnatural amino acid incorporation
described here is complementary to the in vitro approach,
which can accommodate a wider range of analogs at a single
programmed site using chemically misacylated tRNAs [12^
14]. The in vivo approach, on the other hand, is best suited
for substitution by an analog at multiple sites and for obtain-
ing higher protein yields. The method described here allows
routine isolation of tens to hundreds of mg of labeled protein
within days at reasonable cost.
Fig. 2. Cellular concentrations of phenylalanine and p-Br-phe in E.
coli strain AF-IQ[pQE-FS]. Cells were grown to an OD600 = 1, cen-
trifuged, washed twice with NaCl and subjected to treatment as in-
dicated above. Concentration of IPTG = 1 mM; p-Br-phe = 2 mM.
Fig. 1. pheS* allows utilization of p-Br-phe as a substrate for
PheRS. Production of DHFR in the p-Br-phe-supplemented medium
is observed only from plasmid pQE-FS wherein the gene for the
mutant enzyme with relaxed substrate speci¢city, pheS*, is present.
Cells transformed with pQE15 lack the mutant enzyme and cannot
utilize p-Br-phe to make DHFR. In the negative control, which con-
tains neither phe nor p-Br-phe (lanes marked 3), there is no
DHFR, con¢rming auxotrophy for phenylalanine. Concentration of
phe = 20 mg/l; p-Br-phe = 500 mg/l.
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Introduction of aryl bromide functionality opens possibil-
ities for a variety of controlled chemical modi¢cations of en-
gineered proteins, many of which are not possible with the 20
natural amino acids. Aromatic halides are known to undergo
metal-catalyzed coupling, amidation, cyanation and related
reactions, under mild conditions [17^22]. Application of these
chemistries to genetically engineered proteins would allow for
new approaches to side-chain modi¢cation, coupling with var-
ious ligands, immobilization on surfaces, and synthesis of
graft copolymers and cross-linked gels. Bromination may
also provide a new tool for use in X-ray di¡raction studies
of protein structure, though we do not yet know the extent to
which p-Br-phe residues may perturb protein folding. Bromi-
nated pyrimidine bases have been successfully used as anom-
alous scatterers for structure determination of DNA^drug
complexes, DNA^protein complexes and other nucleic acids
[23^27]. We suggest that p-Br-phe is likely to ¢nd similar uses
in crystallographic studies of protein structure.
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